ÌÇÐÄvlog

Object moved to here.

Diagnosis and Treatment of Bipolar Disorder: A Review | Bipolar and Related Disorders | JAMA | ÌÇÐÄvlog

ÌÇÐÄvlog

[Skip to Navigation]
Sign In
1.
Merikangas ÌýKR, Jin ÌýR, He ÌýJP, Ìýet al. ÌýPrevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative.Ìý ÌýArch Gen Psychiatry. 2011;68(3):241-251. doi:
2.
Mcgrath ÌýJJ, Al-hamzawi ÌýA, Alonso ÌýJ, Ìýet al. ÌýAge of onset and cumulative risk of mental disorders: a cross-national analysis of population surveys from 29 countries.Ìý 2023;10(9):668-681. doi:
3.
Clemente ÌýAS, Diniz ÌýBS, Nicolato ÌýR, Ìýet al. ÌýBipolar disorder prevalence: a systematic review and meta-analysis of the literature.Ìý ÌýBraz J Psychiatry. 2015;37(2):155-161. doi:
4.
National Institute of Mental Health. Bipolar disorder. Accessed August 5, 2023.
5.
Loftus ÌýJ, Scott ÌýJ, Vorspan ÌýF, Ìýet al. ÌýPsychiatric comorbidities in bipolar disorders: an examination of the prevalence and chronology of onset according to sex and bipolar subtype.Ìý ÌýJ Affect Disord. 2020;267(267):258-263. doi:
6.
Vieta ÌýE, Salagre ÌýE, Grande ÌýI, Ìýet al. ÌýEarly intervention in bipolar disorder.Ìý ÌýAm J Psychiatry. 2018;175(5):411-426. doi:
7.
Fritz ÌýK, Russell ÌýAMT, Allwang ÌýC, Kuiper ÌýS, Lampe ÌýL, Malhi ÌýGS. ÌýIs a delay in the diagnosis of bipolar disorder inevitable?Ìý ÌýBipolar Disord. 2017;19(5):396-400. doi:
8.
Bipolar and related disorders. In: ÌýDiagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. American Psychiatric Association; 2022. Accessed September 12, 2023. doi:
9.
Krishnan ÌýKRR. ÌýPsychiatric and medical comorbidities of bipolar disorder.Ìý ÌýPsychosom Med. 2005;67(1):1-8. doi:
10.
Tondo ÌýL, Vázquez ÌýGH, Pinna ÌýM, Vaccotto ÌýPA, Baldessarini ÌýRJ. ÌýCharacteristics of depressive and bipolar disorder patients with mixed features.Ìý ÌýActa Psychiatr Scand. 2018;138(3):243-252. doi:
11.
Seo ÌýHJ, Wang ÌýHR, Jun ÌýTY, Woo ÌýYS, Bahk ÌýWM. ÌýFactors related to suicidal behavior in patients with bipolar disorder: the effect of mixed features on suicidality.Ìý ÌýGen Hosp Psychiatry. 2016;39:91-96. doi:
12.
Chan ÌýJKN, Tong ÌýCHY, Wong ÌýCSM, Chen ÌýEYH, Chang ÌýWC. ÌýLife expectancy and years of potential life lost in bipolar disorder: systematic review and meta-analysis.Ìý ÌýBr J Psychiatry. 2022;221(3):567-576. doi:
13.
Miller ÌýJN, Black ÌýDW. ÌýBipolar disorder and suicide: a review.Ìý ÌýCurr Psychiatry Rep. 2020;22(2):6. doi:
14.
Dong ÌýM, Lu ÌýL, Zhang ÌýL, Ìýet al. ÌýPrevalence of suicide attempts in bipolar disorder: a systematic review and meta-analysis of observational studies.Ìý ÌýEpidemiol Psychiatr Sci. 2019;29:e63. doi:
15.
Plans ÌýL, Barrot ÌýC, Nieto ÌýE, Ìýet al. ÌýAssociation between completed suicide and bipolar disorder: a systematic review of the literature.Ìý ÌýJ Affect Disord. 2019;242(242):111-122. doi:
16.
Hayes ÌýJF, Miles ÌýJ, Walters ÌýK, King ÌýM, Osborn ÌýDPJ. ÌýA systematic review and meta-analysis of premature mortality in bipolar affective disorder.Ìý ÌýActa Psychiatr Scand. 2015;131(6):417-425. doi:
17.
Crump ÌýC, Sundquist ÌýK, Winkleby ÌýMA, Sundquist ÌýJ. ÌýComorbidities and mortality in bipolar disorder: a Swedish national cohort study.Ìý ÌýJAMA Psychiatry. 2013;70(9):931-939. doi:
18.
Jackson ÌýJG, Diaz ÌýFJ, Lopez ÌýL, de Leon ÌýJ. ÌýA combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults.Ìý ÌýBipolar Disord. 2015;17(6):575-597. doi:
19.
Daumit ÌýGL, Dalcin ÌýAT, Dickerson ÌýFB, Ìýet al. ÌýEffect of a comprehensive cardiovascular risk reduction intervention in persons with serious mental illness: a randomized clinical trial.Ìý ÌýJAMA Netw Open. 2020;3(6):e207247. doi:
20.
Post ÌýRM, Yatham ÌýLN, Vieta ÌýE, Berk ÌýM, Nierenberg ÌýAA. ÌýBeyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management.Ìý ÌýBipolar Disord. 2019;21(7):650-659. doi:
21.
Malhi ÌýGS, Bell ÌýE, Boyce ÌýP, Ìýet al. ÌýThe 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary.Ìý ÌýBipolar Disord. 2020;22(8):805-821. doi:
22.
Baldessarini ÌýRJ, Tondo ÌýL, Vázquez ÌýGH. ÌýPharmacological treatment of adult bipolar disorder.Ìý ÌýMol Psychiatry. 2019;24(2):198-217. doi:
23.
Yildiz ÌýA, Siafis ÌýS, Mavridis ÌýD, Vieta ÌýE, Leucht ÌýS. ÌýComparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.Ìý Ìý³¢²¹²Ô³¦±ð³Ù Psychiatry. 2023;10(9):693-705. doi:
24.
Kishi ÌýT, Ikuta ÌýT, Matsuda ÌýY, Ìýet al. ÌýPharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.Ìý ÌýMol Psychiatry. 2022;27(2):1136-1144. doi:
25.
Nestsiarovich ÌýA, Gaudiot ÌýCES, Baldessarini ÌýRJ, Vieta ÌýE, Zhu ÌýY, Tohen ÌýM. ÌýPreventing new episodes of bipolar disorder in adults: systematic review and meta-analysis of randomized controlled trials.Ìý ÌýEur Neuropsychopharmacol. 2022;54:75-89. doi:
26.
Ng ÌýF, Mammen ÌýOK, Wilting ÌýI, Ìýet al; International Society for Bipolar Disorders. ÌýThe International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments.Ìý ÌýBipolar Disord. 2009;11(6):559-595. doi:
27.
Yatham ÌýLN, Kennedy ÌýSH, Parikh ÌýSV, Ìýet al. ÌýCanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.Ìý ÌýBipolar Disord. 2018;20(2):97-170. doi:
28.
National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. 2016;(February).
29.
Fountoulakis ÌýKN, Yatham ÌýL, Grunze ÌýH, Ìýet al. ÌýThe International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 2: review, grading of the evidence, and a precise algorithm.Ìý ÌýInt J Neuropsychopharmacol. 2017;20(2):121-179. doi:
30.
Sakurai ÌýH, Kato ÌýM, Yasui-Furukori ÌýN, Ìýet al; Medical Education Panel of the Japanese Society of Clinical Neuropsychopharmacology. ÌýPharmacological management of bipolar disorder: Japanese expert consensus.Ìý ÌýBipolar Disord. 2020;22(8):822-830. doi:
31.
Gutiérrez-Rojas ÌýL, Martínez-Ortega ÌýJM, Pérez-Costillas ÌýL, Jiménez-Fernández ÌýS, Carretero ÌýMD, Gurpegui ÌýM. ÌýIllness insight and medication adherence among patients with bipolar disorder.Ìý ÌýJ Nerv Ment Dis. 2020;208(6):481-487. doi:
32.
Silva ÌýB, Gholam ÌýM, Golay ÌýP, Bonsack ÌýC, Morandi ÌýS. ÌýPredicting involuntary hospitalization in psychiatry: a machine learning investigation.Ìý ÌýEur Psychiatry. 2021;64(1):e48. doi:
33.
Barton ÌýBB, Segger ÌýF, Fischer ÌýK, Obermeier ÌýM, Musil ÌýR. ÌýUpdate on weight-gain caused by antipsychotics: a systematic review and meta-analysis.Ìý ÌýExpert Opin Drug Saf. 2020;19(3):295-314. doi:
34.
Solmi ÌýM, Veronese ÌýN, Zaninotto ÌýL, Ìýet al. ÌýLamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.Ìý ÌýCNS Spectr. 2016;21(5):403-418. doi:
35.
Geddes ÌýJR, Calabrese ÌýJR, Goodwin ÌýGM. ÌýLamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials.Ìý ÌýBr J Psychiatry. 2009;194(1):4-9. doi:
36.
van der Loos ÌýMLM, Mulder ÌýPGH, Hartong ÌýEGTM, Ìýet al; LamLit Study Group. ÌýEfficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.Ìý ÌýJ Clin Psychiatry. 2009;70(2):223-231. doi:
37.
Geddes ÌýJR, Gardiner ÌýA, Rendell ÌýJ, Ìýet al; CEQUEL Investigators and Collaborators. ÌýComparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial.Ìý Ìý³¢²¹²Ô³¦±ð³Ù Psychiatry. 2016;3(1):31-39. doi:
38.
Gitlin ÌýMJ. ÌýAntidepressants in bipolar depression: an enduring controversy.Ìý ÌýInt J Bipolar Disord. 2018;6(1):25. doi:
39.
Pacchiarotti ÌýI, Bond ÌýDJ, Baldessarini ÌýRJ, Ìýet al. ÌýThe International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.Ìý ÌýAm J Psychiatry. 2013;170(11):1249-1262. doi:
40.
Hu ÌýY, Zhang ÌýH, Wang ÌýH, Wang ÌýC, Kung ÌýS, Li ÌýC. ÌýAdjunctive antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis.Ìý ÌýPsychiatry Res. 2022;311(February):114468. doi:
41.
McGirr ÌýA, Vöhringer ÌýPA, Ghaemi ÌýSN, Lam ÌýRW, Yatham ÌýLN. ÌýSafety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials.Ìý Ìý³¢²¹²Ô³¦±ð³Ù Psychiatry. 2016;3(12):1138-1146. doi:
42.
Yatham ÌýLN, Arumugham ÌýSS, Kesavan ÌýM, Ìýet al; BEAM-BD Trial Group. ÌýDuration of adjunctive antidepressant maintenance in bipolar I depression.Ìý ÌýN Engl J Med. 2023;389(5):430-440. doi:
43.
Bahji ÌýA, Hawken ÌýER, Sepehry ÌýAA, Cabrera ÌýCA, Vazquez ÌýG. ÌýECT beyond unipolar major depression: systematic review and meta-analysis of electroconvulsive therapy in bipolar depression.Ìý ÌýActa Psychiatr Scand. 2019;139(3):214-226. doi:
44.
Popiolek ÌýK, Bejerot ÌýS, Brus ÌýO, Ìýet al. ÌýElectroconvulsive therapy in bipolar depression: effectiveness and prognostic factors.Ìý ÌýActa Psychiatr Scand. 2019;140(3):196-204. doi:
45.
Andrade ÌýC, Arumugham ÌýSS, Thirthalli ÌýJ. ÌýAdverse effects of electroconvulsive therapy.Ìý ÌýPsychiatr Clin North Am. 2016;39(3):513-530. doi:
46.
Goodwin ÌýGM, Haddad ÌýPM, Ferrier ÌýIN, Ìýet al. ÌýEvidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology.Ìý ÌýJ Psychopharmacol. 2016;30(6):495-553. doi:
47.
Miura ÌýT, Noma ÌýH, Furukawa ÌýTA, Ìýet al. ÌýComparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis.Ìý Ìý³¢²¹²Ô³¦±ð³Ù Psychiatry. 2014;1(5):351-359. doi:
48.
Post ÌýRM. ÌýThe new news about lithium: an underutilized treatment in the United States.Ìý Ìý±·±ð³Ü°ù´Ç±è²õ²â³¦³ó´Ç±è³ó²¹°ù³¾²¹³¦´Ç±ô´Ç²µ²â. 2018;43(5):1174-1179. doi:
49.
McKnight ÌýRF, Adida ÌýM, Budge ÌýK, Stockton ÌýS, Goodwin ÌýGM, Geddes ÌýJR. ÌýLithium toxicity profile: a systematic review and meta-analysis.Ìý Ìý³¢²¹²Ô³¦±ð³Ù. 2012;379(9817):721-728. doi:
50.
Shine ÌýB, McKnight ÌýRF, Leaver ÌýL, Geddes ÌýJR. ÌýLong-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data.Ìý Ìý³¢²¹²Ô³¦±ð³Ù. 2015;386(9992):461-468. doi:
51.
Tondo ÌýL, Abramowicz ÌýM, Alda ÌýM, Ìýet al. ÌýLong-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters.Ìý ÌýInt J Bipolar Disord. 2017;5(1):27. doi:
52.
Van Alphen ÌýAM, Bosch ÌýTM, Kupka ÌýRW, Hoekstra ÌýR. ÌýChronic kidney disease in lithium-treated patients, incidence and rate of decline.Ìý ÌýInt J Bipolar Disord. 2021;9(1):1-5. doi:
53.
Malhi ÌýGS, Gessler ÌýD, Outhred ÌýT. ÌýThe use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines.Ìý ÌýJ Affect Disord. 2017;217:266-280. doi:
54.
Barroilhet ÌýSA, Ghaemi ÌýSN. ÌýWhen and how to use lithium.Ìý ÌýActa Psychiatr Scand. 2020;142(3):161-172. doi:
55.
Hayes ÌýJF, Pitman ÌýA, Marston ÌýL, Ìýet al. ÌýSelf-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: a UK population-based electronic health records study.Ìý ÌýJAMA Psychiatry. 2016;73(6):630-637. doi:
56.
Velosa ÌýJ, Delgado ÌýA, Finger ÌýE, Berk ÌýM, Kapczinski ÌýF, de Azevedo Cardoso ÌýT. ÌýRisk of dementia in bipolar disorder and the interplay of lithium: a systematic review and meta-analyses.Ìý ÌýActa Psychiatr Scand. 2020;141(6):510-521. doi:
57.
Köhler-Forsberg ÌýO, Rohde ÌýC, Nierenberg ÌýAA, Østergaard ÌýSD. ÌýAssociation of lithium treatment with the risk of osteoporosis in patients with bipolar disorder.Ìý ÌýJAMA Psychiatry. 2022;79(5):454-463. doi:
58.
Anmella ÌýG, Fico ÌýG, Lotfaliany ÌýM, Ìýet al. ÌýRisk of cancer in bipolar disorder and the potential role of lithium: international collaborative systematic review and meta-analyses.Ìý ÌýNeurosci Biobehav Rev. 2021;126(April):529-541. doi:
59.
Grunze ÌýA, Amann ÌýBL, Grunze ÌýH. ÌýEfficacy of carbamazepine and its derivatives in the treatment of bipolar disorder.Ìý ÌýMedicina (Kaunas). 2021;57(5):1-17. doi:
60.
Owens ÌýDC. ÌýSodium valproate in psychiatric practice: time for a change in perception.Ìý ÌýBr J Psychiatry. 2019;215(3):516-518. doi:
61.
Nie ÌýQ, Su ÌýB, Wei ÌýJ. ÌýNeurological teratogenic effects of antiepileptic drugs during pregnancy.Ìý ÌýExp Ther Med. 2016;12(4):2400-2404. doi:
62.
Mari ÌýL, Placidi ÌýF, Romigi ÌýA, Ìýet al. ÌýLevetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy?Ìý ÌýNeurol Sci. 2022;43(3):1993-2001. doi:
63.
Besag ÌýFMC, Vasey ÌýMJ, Sharma ÌýAN, Lam ÌýICH. ÌýEfficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review.Ìý ÌýTher Adv Psychopharmacol. 2021;11:20451253211045870. doi:
64.
Oya ÌýK, Sakuma ÌýK, Esumi ÌýS, Ìýet al. ÌýEfficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design.Ìý ÌýNeuropsychopharmacol Rep. 2019;39(3):241-246. doi:
65.
Lin ÌýCC, Yeh ÌýLL, Pan ÌýYJ. ÌýDegree of exposure to psychotropic medications and mortality in people with bipolar disorder.Ìý ÌýActa Psychiatr Scand. 2023;147(2):186-197. doi:
66.
Lintunen ÌýJ, Lähteenvuo ÌýM, Tanskanen ÌýA, Tiihonen ÌýJ, Taipale ÌýH. ÌýNon-adherence to mood stabilizers and antipsychotics among persons with bipolar disorder: a nationwide cohort study.Ìý ÌýJ Affect Disord. 2023;333(333):403-408. doi:
67.
Keramatian ÌýK, Chakrabarty ÌýT, Yatham ÌýLN. ÌýLong-acting injectable second-generation/atypical antipsychotics for the management of bipolar disorder: a systematic review.Ìý ÌýCNS Drugs. 2019;33(5):431-456. doi:
68.
Chatterton ÌýML, Stockings ÌýE, Berk ÌýM, Barendregt ÌýJJ, Carter ÌýR, Mihalopoulos ÌýC. ÌýPsychosocial therapies for the adjunctive treatment of bipolar disorder in adults: network meta-analysis.Ìý ÌýBr J Psychiatry. 2017;210(5):333-341. doi:
69.
Colom ÌýF, Vieta ÌýE, Sánchez-Moreno ÌýJ, Ìýet al. ÌýGroup psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical tria.Ìý ÌýBr J Psychiatry. 2009;194(6):571.
70.
de Barros Pellegrinelli ÌýK, de O Costa ÌýLF, Silval ÌýKI, Ìýet al. ÌýEfficacy of psychoeducation on symptomatic and functional recovery in bipolar disorder.Ìý ÌýActa Psychiatr Scand. 2013;127(2):153-158. doi:
71.
Chiang ÌýK-J, Tsai ÌýJ-C, Liu ÌýD, Lin ÌýC-H, Chiu ÌýH-L, Chou ÌýK-R. ÌýEfficacy of cognitive-behavioral therapy in patients with bipolar disorder: a meta-analysis of randomized controlled trials.Ìý ÌýPLoS One. 2017;12(5):e0176849. doi:
72.
Miklowitz ÌýDJ, Simoneau ÌýTL, George ÌýEL, Ìýet al. ÌýFamily-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy.Ìý ÌýBiol Psychiatry. 2000;48(6):582-592. doi:
73.
Crowe ÌýM, Porter ÌýR, Inder ÌýM, Ìýet al. ÌýClinical effectiveness trial of adjunctive interpersonal and social rhythm therapy for patients with bipolar disorder.Ìý ÌýAm J Psychother. 2020;73(3):107-114. doi:
74.
Goldstein ÌýTR, Axelson ÌýDA, Birmaher ÌýB, Brent ÌýDA. ÌýDialectical behavior therapy for adolescents with bipolar disorder: a 1-year open trial.Ìý ÌýJ Am Acad Child Adolesc Psychiatry. 2007;46(7):820-830. doi:
75.
Gliddon ÌýE, Cosgrove ÌýV, Berk ÌýL, Ìýet al. ÌýA randomized controlled trial of MoodSwings 2.0: an internet-based self-management program for bipolar disorder.Ìý ÌýBipolar Disord. 2019;21(1):28-39. doi:
76.
Lovas ÌýDA, Schuman-Olivier ÌýZ. ÌýMindfulness-based cognitive therapy for bipolar disorder: a systematic review.Ìý ÌýJ Affect Disord. 2018;240:247-261. doi:
77.
Joslyn ÌýC, Hawes ÌýDJ, Hunt ÌýC, Mitchell ÌýPB. ÌýIs age of onset associated with severity, prognosis, and clinical features in bipolar disorder? a meta-analytic review.Ìý ÌýBipolar Disord. 2016;18(5):389-403. doi:
78.
Altamura ÌýAC, Buoli ÌýM, Caldiroli ÌýA, Ìýet al. ÌýMisdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: a naturalistic study.Ìý ÌýJ Affect Disord. 2015;182:70-75. doi:
79.
Tohen ÌýM, Frank ÌýE, Bowden ÌýCL, Ìýet al. ÌýThe International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders.Ìý ÌýBipolar Disord. 2009;11(5):453-473. doi:
80.
Judd ÌýLL, Akiskal ÌýHS, Schettler ÌýPJ, Ìýet al. ÌýThe long-term natural history of the weekly symptomatic status of bipolar I disorder.Ìý ÌýArch Gen Psychiatry. 2002;59(6):530-537. doi:
81.
Judd ÌýLL, Akiskal ÌýHS, Schettler ÌýPJ, Ìýet al. ÌýA prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.Ìý ÌýArch Gen Psychiatry. 2003;60(3):261-269. doi:
82.
Judd ÌýLL, Schettler ÌýPJ, Akiskal ÌýHS, Ìýet al. ÌýLong-term symptomatic status of bipolar I vs. bipolar II disorders.Ìý ÌýInt J Neuropsychopharmacol. 2003;6(2):127-137. doi:
Views 23,480
Review
°¿³¦³Ù´Ç²ú±ð°ùÌý10, 2023

Diagnosis and Treatment of Bipolar Disorder: A Review

Author Affiliations
  • 1Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston
  • 2Harvard Medical School, Boston, Massachusetts
  • 3Deakin University, IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia
  • 4Department for Affective Disorder, Aarhus University Hospital, Aarhus, Denmark
  • 5Psychosis Research Unit, Aarhus University Hospital, Aarhus, Denmark
  • 6Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
  • 7Depression Clinical and Research Program, Massachusetts General Hospital, Boston
  • 8Orygen, The National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, The University of Melbourne, Melbourne, Australia
JAMA. 2023;330(14):1370-1380. doi:10.1001/jama.2023.18588
Abstract

ImportanceÌý Bipolar disorder affects approximately 8 million adults in the US and approximately 40 million individuals worldwide.

ObservationsÌý Bipolar disorder is characterized by recurrent episodes of depression and mania or hypomania. Bipolar depressive episodes are similar to major depressive episodes. Manic and hypomanic episodes are characterized by a distinct change in mood and behavior during discrete time periods. The age of onset is usually between 15 and 25 years, and depression is the most frequent initial presentation. Approximately 75% of symptomatic time consists of depressive episodes or symptoms. Early diagnosis and treatment are associated with a more favorable prognosis. Diagnosis and optimal treatment are often delayed by a mean of approximately 9 years following an initial depressive episode. Long-term treatment consists of mood stabilizers, such as lithium, valproate, and lamotrigine. Antipsychotic agents, such as quetiapine, aripiprazole, asenapine, lurasidone, and cariprazine, are recommended, but some are associated with weight gain. Antidepressants are not recommended as monotherapy. More than 50% of patients with bipolar disorder are not adherent to treatment. Life expectancy is reduced by approximately 12 to 14 years in people with bipolar disorder, with a 1.6-fold to 2-fold increase in cardiovascular mortality occurring a mean of 17 years earlier compared with the general population. Prevalence rates of metabolic syndrome (37%), obesity (21%), cigarette smoking (45%), and type 2 diabetes (14%) are higher among people with bipolar disorder, contributing to the risk of early mortality. The annual suicide rate is approximately 0.9% among individuals with bipolar disorder, compared with 0.014% in the general population. Approximately 15% to 20% of people with bipolar disorder die by suicide.

Conclusions and RelevanceÌý Bipolar disorder affects approximately 8 million adults in the US. First-line therapy includes mood stabilizers, such as lithium, anticonvulsants, such as valproate and lamotrigine, and atypical antipsychotic drugs, such as quetiapine, aripiprazole, asenapine, lurasidone, and cariprazine.

×